Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSpirax-Sarco Regulatory News (SPX)

Share Price Information for Spirax-Sarco (SPX)

Share Price is delayed by 15 minutes
Get Live Data
6,865.00    170.00 (2.54%)
Bid:
6,865.00
Ask:
6,875.00
Spread: 10.00 (0.146%)
Market Cap: £5.07b
SPX Live PriceLast checked at - London Stock Exchange

Intraday Spirax-Sarco Share Chart

Interim Management Statement

9 Nov 2009 07:00

RNS Number : 1535C
Spirax-Sarco Engineering PLC
09 November 2009
 



Spirax-Sarco Engineering plc

Charlton House

Cheltenham

Glos. GL53 8ER

News Release

Telephone: 01242 521361

Fax: 01242 581470

www.SpiraxSarcoEngineering.com

Monday 9th November 2009

INTERIM MANAGEMENT STATEMENT

Spirax-Sarco Engineering plc, the world leader in the control and efficient use of steam and in peristaltic pumping, issues the following Interim Management Statement based on the period since 1st July 2009.

Trading

Since the half year, the pace of decline in our sales has stabilised. Sales for the year to date through October were down 9% in constant currency against strong results last year. Exchange rates have continued to be favourable and have added 10% to Group revenues in 2009 compared with average exchange rates in calendar year 2008.

Trading margin this year has benefited from exchange rates and, since the end of the half year, has benefited from lower materials costs and reduced operating costs. We have completed the announced headcount reductions which, together with further attrition, means our headcount is now 7% lower than the start of the year. The reductions are largely in manufacturing and administrative support, with cost benefits in the second half year and continuing to be delivered in 2010.

Financial position

We continue to operate with a strong balance sheet. The Group had a net cash balance at 31st October 2009 of £1m despite funding the acquisition of MasoSine in August for £22m and Intervalf in October for £3m. There has been no material change in the financial position of the Group during the period. Capital investment is well above the level in recent years as we continue to invest in projects with good returns to deliver more efficient manufacturing processes and capacity expansion, particularly in developing markets.

Outlook

Our strong cash position has enabled us to continue to make investments in developing new products, expanding our market penetration and improving operating efficiency, even through this difficult period. The Group's strong customer value proposition and diversity of end user markets, customers, products and geographic spread, give us confidence in our future prospects.

Enquiries:

Mark E Vernon, Chief Executive

David Meredith, Director Finance

Tel: 01242 535236

About Spirax Sarco

Spirax-Sarco Engineering plc is the world leader in both steam system management and peristaltic pumping. The Company provides a broad range of fluid control products, engineered packages, site services and systems expertise for its diverse range of over 100,000 industrial and institutional customers. The Company helps its customers to optimise production capacity, reduce energy costs and emissions, improve product quality and enhance the safety of their operations. Spirax Sarco is headquartered in Cheltenham, England, has strategically located manufacturing plants around the world and employs approximately 4,200 people, of whom 1,200 are direct sales and service engineers. Its shares have been listed on the London Stock Exchange since 1959 (symbol: SPX). Further information can be found at www.spiraxsarcoengineering.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBLBDBXUGGGCL
Date   Source Headline
21st Nov 20173:08 pmRNSDirector/PDMR Shareholding
21st Nov 20177:00 amRNSTrading Statement
14th Nov 201710:39 amRNSDirector/PDMR Shareholding
16th Oct 20175:35 pmRNSDirector/PDMR Shareholding
29th Sep 20173:36 pmRNSHolding(s) in Company
9th Aug 20177:00 amRNSHalf-year Report
4th Jul 20177:00 amRNSCompletion of Acquisition
23rd Jun 20179:11 amRNSTotal Voting Rights
20th Jun 20173:59 pmRNSHolding(s) in Company
12th Jun 20172:20 pmRNSDirector/PDMR Shareholding
5th Jun 20179:08 amRNSDirector/PDMR Shareholding
26th May 20177:00 amRNSAcquisition of Chromalox for US$415 million
9th May 20174:30 pmRNSResult of AGM
9th May 20177:00 amRNSTrading Statement
4th May 20174:30 pmRNSHolding(s) in Company
3rd May 20177:00 amRNSCompletion of Acquisition
26th Apr 20178:42 amRNSHolding(s) in Company
25th Apr 20179:10 amRNSHolding(s) in Company
19th Apr 20173:55 pmRNSHolding(s) in Company
18th Apr 20173:58 pmRNSHolding(s) in Company
3rd Apr 20177:30 amRNSAcquisition
24th Mar 20174:44 pmRNSTotal Voting Rights
23rd Mar 20171:45 pmRNSDirector/PDMR Shareholding
17th Mar 20174:04 pmRNSDirector/PDMR Shareholding
9th Mar 20177:00 amRNSFinal Results
30th Nov 20167:00 amRNSAcquisition
22nd Nov 20167:00 amRNSTrading Statement
17th Nov 20164:23 pmRNSDirector/PDMR Shareholding
14th Nov 20168:30 amRNSDr Krishnamurthy Rajagopal
10th Nov 201611:40 amRNSListing Application
8th Nov 201611:57 amRNSChange of Director Details
4th Nov 20164:27 pmRNSTotal Voting Rights
28th Oct 20167:00 amRNSBoard Succession Changes
17th Oct 20162:49 pmRNSAdditional Listing
14th Oct 20165:03 pmRNSDirector/PDMR Shareholding
14th Oct 20163:20 pmRNSTotal Voting Rights
14th Oct 20163:17 pmRNSBlock listing Interim Review
6th Oct 201611:48 amRNSNotification of Release Date - Trading Statement
8th Sep 201612:44 pmRNSTotal Voting Rights
18th Aug 20168:30 amRNSBoard Appointment
12th Aug 20163:51 pmRNSDirector/PDMR Shareholding
9th Aug 20167:05 amRNSSpirax Sarco acquires assets of Hiter for £3.9 m
9th Aug 20167:00 amRNS2016 Half Year Results
5th Aug 20162:56 pmRNSTotal Voting Rights
1st Jul 201611:43 amRNSTotal Voting Rights
29th Jun 20169:29 amRNSNotice of Results
21st Jun 20165:40 pmRNSDirector/PDMR Shareholding
10th Jun 20162:59 pmRNSHolding(s) in Company
2nd Jun 20164:20 pmRNSAdditional Listing
2nd Jun 20163:28 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.